Drug intelligence / Profile preview

TFG

Development stage: Unknown
Administration: Oral

Overview

TFG, in the context of a clinical trial (NCT03057899), refers to a mixed herbal extract composed of fenugreek seed and Lespedeza cuneata. It is investigated for its efficacy and safety in treating testosterone deficiency syndrome (TDS). The fenugreek seed component is known to contain various compounds, including steroidal saponins (like diosgenin and furostanol glycosides), choline, vitamins, and amino acids, which are believed to contribute to its anabolic and androgenic activity. This activity is thought to be mediated by increasing testosterone, including free testosterone, and potentially by acting as an incomplete 5-alpha reductase and aromatase inhibitor. The extract is administered orally in capsule form.

Other names: mixed extract of fenugreek seed and Lespedeza cuneata

Beyond the preview

Go deeper on TFG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TFG.

Explore the full profile